Evidence map›Paper›PMID 30778334›Full record

ReviewFrontiers in endocrinology2019

Interventions to Address Environmental Metabolism-Disrupting Chemicals: Changing the Narrative to Empower Action to Restore Metabolic Health.

Robert M Sargis, Jerrold J Heindel, Vasantha Padmanabhan

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Water pollution and the brain.Clinics (Sao Paulo, Brazil) · 2024
    Article
  13. Article
  14. Hormonal Injustice: Environmental Toxicants as Drivers of Endocrine Health Disparities.Endocrinology and metabolism clinics of North America · 2023
    Review
  15. Article
  16. Article
  17. Critical Overview on Endocrine Disruptors in Diabetes Mellitus.International journal of molecular sciences · 2023
    Review
  18. Article
  19. Stress and human health in diabetes: A report from the 19Journal of clinical and translational science · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Robert M SargisDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, United States.
Jerrold J HeindelProgram on Endocrine Disruption Strategies, Commonweal, Bolinas, CA, United States.
Vasantha PadmanabhanDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, United States.
Commonweal · USUniversity of Illinois Chicago · USUniversity of Michigan–Ann Arbor · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Strategic Vision & Impact on Environmental HealthP30ES017885 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Dana Dolinoy · 2011 to 2026
$21.3M
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Project 3: Developmental Exposures and Diet: Epigenetics of Metabolic SyndromeP01ES022844 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PADMANABHAN, VASANTHA, PETERSON, KAREN EILEEN · 2013 to 2018
$3.9M
Selenoproteins in Arsenic-Induced Metabolic DysfunctionR01ES028879 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARGIS, ROBERT M · 2018 to 2022
$2.7M
NIDDK NIH HHS P30 DK020572NIEHS NIH HHS P01 ES022844NIEHS NIH HHS P30 ES017885NIEHS NIH HHS P30 ES027792NIEHS NIH HHS R01 ES028879
6 · The paper itself

Abstract

Metabolic disease rates have increased dramatically over the last four decades. Classic understanding of metabolic physiology has attributed these global trends to decreased physical activity and caloric excess; however, these traditional risk factors insufficiently explain the magnitude and rapidity of metabolic health deterioration. Recently, the novel contribution of environmental metabolism-disrupting chemicals (MDCs) to various metabolic diseases (including obesity, diabetes, and non-alcoholic fatty liver disease) is becoming recognized. As this burgeoning body of evidence has matured, various organic and inorganic pollutants of human and natural origin have emerged as metabolic disease risk factors based on population-level and experimental data. Recognition of these heretofore underappreciated metabolic stressors now mandates that efforts to mitigate the devastating consequences of metabolic disease include dedicated efforts to address environmental drivers of disease risk; however, there have not been adequate recommendations to reduce exposures or to mitigate the effects of exposures on disease outcomes. To address this knowledge gap and advance the clinical translation of MDC science, herein discussed are behaviors that increase exposures to MDCs, interventional studies to reduce those exposures, and small-scale clinical trials to reduce the body burden of MDCs. Also, we discuss evidence from cell-based and animal studies that provide insights into MDC mechanisms of action, the influence of modifiable dietary factors on MDC toxicity, and factors that modulate MDC transplacental carriage as well as their impact on metabolic homeostasis. A particular emphasis of this discussion is on critical developmental windows during which short-term MDC exposure can elicit long-term disruptions in metabolic health with potential inter- and transgenerational effects. While data gaps remain and further studies are needed, the current state of evidence regarding interventions to address MDC exposures illuminates approaches to address environmental drivers of metabolic disease risk. It is now incumbent on clinicians and public health agencies to incorporate this knowledge into comprehensive strategies to address the metabolic disease pandemic.

Indexed as

diabetesendocrine disruptorinterventionmetabolismmetabolism-disrupting chemicalnon-alcoholic fatty liver diseaseobesity

Identifiers

PMID30778334
PMCPMC6369180
OpenAlexW2914776112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.